284 related articles for article (PubMed ID: 7500030)
1. HLA-A2 subtypes are functionally distinct in peptide binding and presentation.
Barouch D; Friede T; Stevanović S; Tussey L; Smith K; Rowland-Jones S; Braud V; McMichael A; Rammensee HG
J Exp Med; 1995 Dec; 182(6):1847-56. PubMed ID: 7500030
[TBL] [Abstract][Full Text] [Related]
2. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
3. The kinetics of peptide binding to HLA-A2 and the conformation of the peptide-A2 complex can be determined by amino acid side chains on the floor of the peptide binding groove.
Shimojo N; Anderson RW; Mattson DH; Turner RV; Coligan JE; Biddison WE
Int Immunol; 1990; 2(3):193-200. PubMed ID: 2088485
[TBL] [Abstract][Full Text] [Related]
4. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
5. Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains.
Fruci D; Rovero P; Falasca G; Chersi A; Sorrentino R; Butler R; Tanigaki N; Tosi R
Hum Immunol; 1993 Nov; 38(3):187-92. PubMed ID: 8106276
[TBL] [Abstract][Full Text] [Related]
6. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
[TBL] [Abstract][Full Text] [Related]
7. HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides.
Carreno BM; Anderson RW; Coligan JE; Biddison WE
Proc Natl Acad Sci U S A; 1990 May; 87(9):3420-4. PubMed ID: 2333291
[TBL] [Abstract][Full Text] [Related]
8. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A
Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932
[TBL] [Abstract][Full Text] [Related]
9. Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling.
Lim JS; Kim S; Lee HG; Lee KY; Kwon TJ; Kim K
Mol Immunol; 1996 Feb; 33(2):221-30. PubMed ID: 8649443
[TBL] [Abstract][Full Text] [Related]
10. The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping.
Carreno BM; Koenig S; Coligan JE; Biddison WE
Mol Immunol; 1992 Sep; 29(9):1131-40. PubMed ID: 1379681
[TBL] [Abstract][Full Text] [Related]
11. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.
Torikai H; Akatsuka Y; Miyauchi H; Terakura S; Onizuka M; Tsujimura K; Miyamura K; Morishima Y; Kodera Y; Kuzushima K; Takahashi T
Bone Marrow Transplant; 2007 Jul; 40(2):165-74. PubMed ID: 17530010
[TBL] [Abstract][Full Text] [Related]
12. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB
J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791
[TBL] [Abstract][Full Text] [Related]
13. Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B.
Rojo S; García F; Villadangos JA; López de Castro JA
J Exp Med; 1993 Mar; 177(3):613-20. PubMed ID: 8436905
[TBL] [Abstract][Full Text] [Related]
14. Presentation of three different viral peptides is determined by common structural features of the human lymphocyte antigen-A2.1 molecule.
Utz U; Biddison WE
J Immunother (1991); 1992 Oct; 12(3):180-2. PubMed ID: 1445808
[TBL] [Abstract][Full Text] [Related]
15. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
17. Peptide sequences binding to MHC class I proteins.
Smith MH; Lam KS; Hersh EM; Lebl M; Grimes WJ
Mol Immunol; 1994 Dec; 31(18):1431-7. PubMed ID: 7823969
[TBL] [Abstract][Full Text] [Related]
18. Nonclassical HLA-G molecules are classical peptide presenters.
Diehl M; Münz C; Keilholz W; Stevanović S; Holmes N; Loke YW; Rammensee HG
Curr Biol; 1996 Mar; 6(3):305-14. PubMed ID: 8805247
[TBL] [Abstract][Full Text] [Related]
19. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products.
Tanigaki N; Fruci D; Chersi A; Falasca G; Tosi R; Butler RH
Hum Immunol; 1994 Mar; 39(3):155-62. PubMed ID: 8026983
[TBL] [Abstract][Full Text] [Related]
20. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
